Bearing in mind the recent extension of gliflozin use for the treatment of heart failure, greater attention to the metabolic aspects should also be posed for AF patients: indeed, SGLT2 inhibitors have shown to reduce the risk of new-onset AF along with a reduction in body weight [24,25]. Here, SLC5A2 is linked to heart failure.